RJA
CYTK icon

Raymond James & Associates’s Cytokinetics CYTK Stock Holding History

Raymond James & Associates’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$217K Buy
4,107
+234
+6% +$13K ﹤0.01% 3597
2024
Q2 		$210K Sell
3,873
-4,031
-51% -$243K ﹤0.01% 3578
2024
Q1 		$554K Sell
7,904
-6,923
-47% -$535K ﹤0.01% 3003
2023
Q4 		$1.24M Sell
14,827
-1,861
-11% -$67.4K ﹤0.01% 2392
2023
Q3 		$492K Sell
16,688
-219
-1% -$7.29K ﹤0.01% 2903
2023
Q2 		$552K Sell
16,907
-512
-3% -$18.9K ﹤0.01% 2878
2023
Q1 		$613K Buy
17,419
+11
+0.1% +$449 ﹤0.01% 2793
2022
Q4 		$798K Buy
17,408
+2,752
+19% +$118K ﹤0.01% 2564
2022
Q3 		$710K Sell
14,656
-1,025
-7% -$49.3K ﹤0.01% 2604
2022
Q2 		$616K Buy
15,681
+360
+2% +$14.5K ﹤0.01% 2776
2022
Q1 		$564K Buy
+15,321
New +$544K ﹤0.01% 3002
2020
Q4 		– Sell
-9,784
Closed -$212K – 3789
2020
Q3 		$212K Buy
+9,784
New +$229K ﹤0.01% 3176
2016
Q4 		– Sell
-11,450
Closed -$105K – 3265
2016
Q3 		$105K Sell
11,450
-1,000
-8% -$10.4K ﹤0.01% 2987
2016
Q2 		$118K Sell
12,450
-166
-1% -$1.36K ﹤0.01% 2775
2016
Q1 		$89K Buy
+12,616
New +$92.2K ﹤0.01% 2734

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Raymond James & Associates's CYTK Position: Q3 2024 in Review

Raymond James & Associates increased its Cytokinetics (CYTK) stake by 6% in Q3 2024, buying an estimated $13K and bringing the position to 4,107 shares worth $217K. The position accounts for ﹤0.01% of the portfolio, ranked #3597.

Raymond James & Associates first reported a position in CYTK in Q1 2016 and has held it in 15 quarters since. The position peaked at $1.24M in Q4 2023. 347 funds tracked by Wall St. Rank hold CYTK as of Q3 2024.

  • Raymond James & Associates held 4,107 shares of Cytokinetics worth $217K as of Q3 2024.
  • Raymond James & Associates bought 234 Cytokinetics shares in Q3 2024, an estimated $13K.
  • Cytokinetics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3597 holding.
  • Raymond James & Associates first reported a position in Cytokinetics in Q1 2016 and has held it in 15 quarters since.
  • Raymond James & Associates's Cytokinetics position peaked at $1.24M in Q4 2023.
  • 347 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.